Overview

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 30 FlexPen® under normal clinical practice conditions.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin, Isophane